1694731-93-5 Usage
Description
Azido-PEG4-CH2CO2H is a versatile linker molecule composed of an azido group, a PEG4 (polyethylene glycol) chain, and a carboxylic acid group. The azido group can participate in Click Chemistry reactions with alkyne compounds in the presence of a copper catalyst, while the carboxylic acid group can react with primary amine groups using activation methods such as HATU or EDC. The PEG4 chain enhances the molecule's solubility in aqueous solutions, making it suitable for various applications in different industries.
Uses
Used in Bioconjugation:
Azido-PEG4-CH2CO2H is used as a bioconjugation agent for the covalent attachment of biomolecules, such as proteins or peptides, to other molecules or surfaces. The azido group facilitates Click Chemistry reactions, allowing for the efficient and specific coupling of target molecules.
Used in Drug Delivery Systems:
In the pharmaceutical industry, Azido-PEG4-CH2CO2H is used as a component in the design of drug delivery systems. The PEG4 chain improves the solubility and bioavailability of drug molecules, while the azido and carboxylic acid groups enable the attachment of drugs or targeting moieties through Click Chemistry or amide bond formation.
Used in Materials Science:
In materials science, Azido-PEG4-CH2CO2H is used as a building block for the development of functional polymers and hydrogels. The azido group allows for the creation of complex network structures through Click Chemistry, while the PEG4 chain contributes to the overall properties of the material, such as swelling behavior and mechanical strength.
Used in Diagnostics:
Azido-PEG4-CH2CO2H is used as a labeling agent in diagnostic applications. The azido group can be used to attach detection moieties, such as fluorescent dyes or radioisotopes, to biomolecules for various detection and imaging techniques.
Used in Chemical Synthesis:
In chemical synthesis, Azido-PEG4-CH2CO2H serves as an intermediate or a protecting group for the synthesis of more complex molecules. The azido and carboxylic acid groups provide versatile points for further modification and functionalization of the molecule.
Check Digit Verification of cas no
The CAS Registry Mumber 1694731-93-5 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,6,9,4,7,3 and 1 respectively; the second part has 2 digits, 9 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 1694731-93:
(9*1)+(8*6)+(7*9)+(6*4)+(5*7)+(4*3)+(3*1)+(2*9)+(1*3)=215
215 % 10 = 5
So 1694731-93-5 is a valid CAS Registry Number.
1694731-93-5Relevant articles and documents
Combretastatin A4-camptothecin micelles as combination therapy for effective anticancer activity
Assali, Mohyeddin,Kittana, Naim,Qasem, Sahar Alhaj,Adas, Raghad,Saleh, Doaa,Arar, Asala,Zohud, Osayd
, p. 1055 - 1061 (2019)
Cancer is a major worldwide health problem, for which chemotherapy is a common treatment option. However drug toxicity and the development of resistance to chemotherapy are two main challenges associated with the traditional anticancer drugs. Combined pharmacological therapy based on different mechanisms might be an effective strategy in cancer treatment, and could exhibit a synergistic therapeutic efficacy. Herein, we aim to combine combretastatin A4 (CA4) and camptothecin (Cpt) chemically into a codrug through two hydrophilic linkers utilizing click chemistry to improve their water solubility and anticancer activity. The synthesized amphiphilic structure could self-assemble into a micelle structure as confirmed by atomic force microscopy (AFM) and dynamic light scattering (DLS), which showed a high stability and improved water solubility at pH 7.4, with a low critical micelle concentration (CMC) value of 0.9 mM. Moreover, in vitro hydrolysis was observed upon incubation of the hybrid compound with an esterase enzyme, which suggested a complete disassembly into the starting active drugs. Finally, cytotoxicity studies on HeLa cancer cells showed that the codrug demonstrated an enhanced (five fold) cytotoxicity as compared with the free drugs. In addition the combination index (CI) was 1, which suggests a synergistic activity for the codrug. Moreover, the tested concentrations of the codrug were not significantly cytotoxic to a noncancerous fibroblast cell line. The imaging of HeLa cells treated with FITC-loaded micelles showed a rapid internalization. In conclusion, the codrug of CA4 and Cpt might be a potential novel anticancer drug as it demonstrated a synergistic cytotoxic activity that might spare noncancerous cells.
